{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-171957","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2022-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.813233+00:00","generated_at":"2026-06-25T02:48:10.635819+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Fulcrum reports positive Phase 1b data for FTX-6058 in sickle cell disease; HbF up 6.3%","bullets":["FTX-6058 achieved up to 6.3% increase in fetal hemoglobin (HbF) over baseline in Phase 1b trial.","Three evaluable subjects all showed HbF increases by day 28; maximal levels may not yet be reached.","FTX-6058 was generally well-tolerated; no serious TEAEs or discontinuations due to TEAEs.","Company plans to complete enrollment in current and two additional dose cohorts by end of 2022, with registrational trial start in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-171957","json":"https://secwatch.observer/filing/0001193125-22-171957.json","markdown":"https://secwatch.observer/filing/0001193125-22-171957.md","text":"https://secwatch.observer/filing/0001193125-22-171957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522171957/0001193125-22-171957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522171957/d369471d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:48:10.635819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}